1. Abrams J, Rayner A, Wiernik P, Parkinson D (1989) High dose Interleukin-2 without lymphokine activated killer cells: inactive in advanced renal call cancer. Proc Am Soc Clin Oncol 30: 380
2. Aso Y, Tazaki H, Umeda T, Marumo K (1991) Treatment of advanced renal cell carcinoma by systemic low-dose recombinant interleukin-2 In: Debruyne FMJ, Bukowski RM, Pontes JE, Mulder PHM (eds) Immunotherapy of renal cell carcinoma. Springer, Berlin Heidelberg New York Tokyo, pp 91–103
3. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM (1988) Hypothyroidism after treatment with Interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557–1563
4. Atzpodien J, Kirchner H (1990) Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68: 1–11
5. Atzpodien J, Körfer A, Kirchner H (1991) Interleukin-2 and interferon alpha in renal cell carcinoma: the European experience. The second international symposium: immunobiology of renal cell carcinoma. Oct 21 and 22, 1991. Cleveland, Ohio/USA